Pfizer Raises 2025 Profit Outlook Amid Cost Savings and Tariff Challenges
TL;DR Summary
Pfizer has raised its 2025 EPS guidance to $2.90–$3.10 and aims for margin expansion through $7.7 billion in cost savings by 2027, with CEO Albert Bourla highlighting progress in R&D, portfolio expansion, and improved margins.
- Pfizer raises 2025 EPS guidance to $2.90–$3.10 while targeting margin expansion through $7.7B cost savings by 2027 Seeking Alpha
- Pfizer hikes 2025 profit outlook on cost cuts, strong quarterly results CNBC
- Pfizer Stock Rises as Earnings Smash Expectations. Guidance Hiked Amid Tariffs. Barron's
- Why Shares of Pfizer Soared Today Yahoo Finance
- Pfizer boosts profit estimate, even as the drug giant absorbs tariffs MarketWatch
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
1 min
vs 2 min read
Condensed
83%
204 → 35 words
Want the full story? Read the original article
Read on Seeking Alpha